As depicted in Fig. 4B, MRF/magnet application induced a significant increase in the percentage of CD8(+)-tetramer+-CD25+ T cells to the Renca-HA-MRF/magnet-treated tumor, and not in control groups (Fig. 4B) with approximately 13-fold increase in overall total numbers of HA-Tg-CD8(+) T cells homing to the primary tumor (Fig. 4C). The gene discussed is CD8A; the disease is neoplasm.